The North America anticoagulants market is expected to register a CAGR of 8.16%, during the forecast period of 2021 to 2028. The region’s market growth is accredited to factors like the increased levels of awareness regarding novel therapeutics, the easy availability of treatments, the large number of healthcare professionals, and the strong presence of diagnostic centers and hospitals.

NORTH AMERICA ANTICOAGULANTS MARKET FORECAST 2021-2028

North America Anticoagulants Market by Application (Atrial Fibrillation & Heart Attack, Pulmonary Embolism (Pe), Deep Vein Thrombosis (Dvt), Stroke, Other Applications) by Route of Administration (Oral Anticoagulants, Injectable Anticoagulants) by Drug Class (Noacs (Xarelto, Eliquis, Pradaxa, Savaysa & Lixiana, Bevyxxa), Heparins & Low-molecular-weight Heparins (Lmwhs), Vitamin K Antagonists, Other Drug Class) and by Geography.

Request free sample

Report Summary

The North America anticoagulants market is expected to register a CAGR of 8.16%, during the forecast period of 2021 to 2028. The region’s market growth is accredited to factors like the increased levels of awareness regarding novel therapeutics, the easy availability of treatments, the large number of healthcare professionals, and the strong presence of diagnostic centers and hospitals.
north-america-anticoagulants-market

To learn more about this report, request a free sample copy

The North America anticoagulants market growth is assessed by evaluating the United States and Canada. The United States is anticipated to observe significant market growth during the forecast years, with the increased prevalence of cardiac diseases, in addition to numerous other blood disorders augmenting the country’s market revenue. Moreover, the United States’ well-established healthcare infrastructure, the surging healthcare expenditure, as well as the favorable reimbursement policies, are likely to bolster the region’s overall market growth.

According to the data issued by the Centers for Disease Control and Prevention (CDC), at least 60,000 to 100,000 Americans die because of DVT/PE, also termed as venous thromboembolism. Although the exact number of patients affected with DVT/PT remains unknown, nearly 900,000 people, or 1 to 2 per 1,000 people, are annually affected in the United States. Hence, these factors are projected to drive the country’s anticoagulants market growth, during the forecast period.

With its headquarters in the United States, Johnson & Johnson is an investment holding company, mainly focused on healthcare products. It is involved in the research and development, in addition to manufacturing and marketing personal care products, as well as surgical and pharmaceutical equipment. The enterprise operates through business segments, including, medical devices, consumer, and pharmaceuticals.

 

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    Table of Contents

    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      •    KEY DRIVERS
        • SURGING PREVALENCE OF CHRONIC DISEASE
        • ADVANCEMENTS IN TECHNOLOGY
        • RISING APPROVAL OF NOVEL ORAL ANTICOAGULANTS (NOACS)
      •    KEY RESTRAINTS
        • SIDE EFFECTS ASSOCIATED WITH ANTICOAGULANTS TREATMENT
        • HIGH PRICE OF NOACS
        • STRINGENT GOVERNMENT REGULATIONS
    1. KEY ANALYTICS
      •    PORTER’S FIVE FORCES ANALYSIS
        • THREAT OF NEW ENTRY
        • THREAT OF SUBSTITUTION
        • BUYER’S POWER
        • SUPPLIER’S POWER
        • COMPETITIVE RIVALRY
      • IMPACT OF COVID-19 ON ANTICOAGULANTS MARKET
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • KEY INVESTMENT INSIGHTS
    2. MARKET BY APPLICATION
      • ATRIAL FIBRILLATION & HEART ATTACK
      • PULMONARY EMBOLISM (PE)
      • DEEP VEIN THROMBOSIS (DVT)
      • STROKE
      • OTHER APPLICATIONS
    3. MARKET BY ROUTE OF ADMINISTRATION
      • ORAL ANTICOAGULANTS
      • INJECTABLE ANTICOAGULANTS
    4. MARKET BY DRUG CLASS
      • NOACS
      • HEPARINS & LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS)
      • VITAMIN K ANTAGONISTS
      • OTHER DRUG CLASS
    5. GEOGRAPHICAL ANALYSIS
      •    NORTH AMERICA
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        •    COUNTRY ANALYSIS
          • UNITED STATES
          • CANADA
    1. COMPETITIVE LANDSCAPE
      •    KEY STRATEGIC DEVELOPMENTS
        • MERGER & ACQUISITIONS
        • PRODUCT LAUNCH & DEVELOPMENTS
        • PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
        • BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
      •    COMPANY PROFILE
        • ABBOTT LABORATORIES
        • ALEXION PHARMACEUTICAL INC
        • ASPEN PHARMACARE HOLDINGS LIMITED
        • BAYER AG
        • BOEHRINGER INGELHEIM GMBH
        • BRISTOL-MYERS SQUIBB COMPANY
        • DAIICHI SANKYO
        • REDDY’S LABORATORIES
        • GLAXOSMITHKLINE PLC
        • JOHNSON & JOHNSON
        • LEO PHARMA AS
        • MERCK & CO
        • NOVARTIS AG
        • PFIZER INC
        • SANOFI

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – ANTICOAGULANTS

    TABLE 2: NORTH AMERICA ANTICOAGULANTS MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 3: NORTH AMERICA ANTICOAGULANTS MARKET, BY APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 4: NORTH AMERICA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 5: NORTH AMERICA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 6: NORTH AMERICA ANTICOAGULANTS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 7: NORTH AMERICA ANTICOAGULANTS MARKET, BY DRUG CLASS, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 8: NORTH AMERICA ANTICOAGULANTS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 9: NORTH AMERICA ANTICOAGULANTS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 10: LEADING PLAYERS OPERATING IN NORTH AMERICA ANTICOAGULANTS MARKET

    LIST OF FIGURES

    FIGURE 1: CHRONIC CONDITIONS IN PATIENTS HOSPITALIZED WITH COVID-19 IN THE UNITED STATES

    FIGURE 2: PORTER’S FIVE FORCE ANALYSIS

    FIGURE 3: OPPORTUNITY MATRIX

    FIGURE 4: VENDOR LANDSCAPE

    FIGURE 5: KEY INVESTMENT INSIGHTS

    FIGURE 6: NORTH AMERICA ANTICOAGULANTS MARKET, BY APPLICATION, IN 2020

    FIGURE 7: NORTH AMERICA ANTICOAGULANTS MARKET, BY ATRIAL FIBRILLATION & HEART ATTACK, 2021-2028 (IN $ MILLION)

    FIGURE 8: NORTH AMERICA ANTICOAGULANTS MARKET, BY PULMONARY EMBOLISM (PE), 2021-2028 (IN $ MILLION)

    FIGURE 9: NORTH AMERICA ANTICOAGULANTS MARKET, BY DEEP VEIN THROMBOSIS (DVT), 2021-2028 (IN $ MILLION)

    FIGURE 10: NORTH AMERICA ANTICOAGULANTS MARKET, BY STROKE, 2021-2028 (IN $ MILLION)

    FIGURE 11: NORTH AMERICA ANTICOAGULANTS MARKET, BY OTHER APPLICATIONS, 2021-2028 (IN $ MILLION)

    FIGURE 12: NORTH AMERICA ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, IN 2020

    FIGURE 13: NORTH AMERICA ANTICOAGULANTS MARKET, BY ORAL ANTICOAGULANTS, 2021-2028 (IN $ MILLION)

    FIGURE 14: NORTH AMERICA ANTICOAGULANTS MARKET, BY INJECTABLE ANTICOAGULANTS, 2021-2028 (IN $ MILLION)

    FIGURE 15: NORTH AMERICA ANTICOAGULANTS MARKET, BY DRUG CLASS, IN 2020

    FIGURE 16: NORTH AMERICA ANTICOAGULANTS MARKET, BY NOACS, 2021-2028 (IN $ MILLION)

    FIGURE 17: NORTH AMERICA ANTICOAGULANTS MARKET, BY HEPARINS & LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS), 2021-2028 (IN $ MILLION)

    FIGURE 18: NORTH AMERICA ANTICOAGULANTS MARKET, BY VITAMIN K ANTAGONISTS, 2021-2028 (IN $ MILLION)

    FIGURE 19: NORTH AMERICA ANTICOAGULANTS MARKET, BY OTHER DRUG CLASS, 2021-2028 (IN $ MILLION)

    FIGURE 20: NORTH AMERICA ANTICOAGULANTS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

    FIGURE 21: THE UNITED STATES ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

    FIGURE 22: CANADA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

    Segmentation

    1. GEOGRAPHICAL ANALYSIS
      •    NORTH AMERICA
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        •    COUNTRY ANALYSIS
          • UNITED STATES
          • CANADA
    1. MARKET BY APPLICATION
      • ATRIAL FIBRILLATION & HEART ATTACK
      • PULMONARY EMBOLISM (PE)
      • DEEP VEIN THROMBOSIS (DVT)
      • STROKE
      • OTHER APPLICATIONS
    2. MARKET BY ROUTE OF ADMINISTRATION
      • ORAL ANTICOAGULANTS
      • INJECTABLE ANTICOAGULANTS
    3. MARKET BY DRUG CLASS
      • NOACS
      • HEPARINS & LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS)
      • VITAMIN K ANTAGONISTS
      • OTHER DRUG CLASS

    Request Free Sample

    To request a free sample copy of this report, please complete the form below :
    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type

      Get In Touch

      Inquire Before Buying

      Customization

      Inkwood Research delivers customized reports as per the client's requirement to provide them with an edge in the competitive market

      Request Customization

      RELATED REPORTS